Do you want to read an article? Please log in or register.
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
Diabetes - GeneralType 2 Diabetes
COMMENTED
Related content
RECOMMENDED
Type 2 Diabetes
Birth Weight and Risk of Type 2 Diabetes Mellitus, Cardiovascular Disease, and Hypertension in Adults: A Meta-Analysis of 7 646 267 Participants From 135 Studies
J Am Heart Assoc.
Knop MR, Geng TT, Gorny AW, Ding R, Li C, Ley SH, Huang T
doi: 10.1161/JAHA.118.008870.
Type 2 Diabetes
Heart failure among people with Type 2 diabetes mellitus: real-world data of 289 954 people from a diabetes database
Diabet Med.
Stoyanova D, Stratmann B, Schwandt A, Heise N, Mühldorfer S, Ziegelasch HJ, Zimmermann A, Tschoepe D, Holl RW, DPV Initiative
doi: 10.1111/dme.13915.
COMMENTED
Type 2 Diabetes
Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America
Circulation.
Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, Deswal A, Dickson VV, Kosiborod MN, Lekavich CL, McCoy RG, Mentz RJ, Piña IL, American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and the Heart Failure Society of America.
doi: 10.1161/
COMMENTED
Diabetes - GeneralType 2 Diabetes
Use of Vascular Assessments and Novel Biomarkers to Predict Cardiovascular Events in Type 2 Diabetes: The SUMMIT VIP Study
Diabetes Care.
Shore AC, Colhoun HM, Natali A, Palombo C, Khan F, Östling G, Aizawa K, Kennbäck C, Casanova F, Persson M, Gooding K, Gates PE, Looker H, Dove F, Belch J, Pinnola S, Venturi E, Kozakova M, Goncalves I, Kravic J, Björkbacka H, Nilsson J; SUMMIT Consortium
doi: 10.2337/dc18-0185.
COMMENTED
Type 2 Diabetes
Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
doi: 10.1016/S2213-8587(20)30038-3.
COMMENTED
Type 2 Diabetes
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial
Circulation.
Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V, CREDENCE study investigators.
doi: 10.1161/
Diabetes - GeneralType 2 Diabetes
Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus
J Am Heart Assoc.
Wolsk E, Claggett B, Pfeffer MA, Diaz R, Dickstein K, Gerstein HC, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Køber L
doi: 10.1161/JAHA.116.004743.
Diabetes - GeneralType 2 Diabetes
The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial
Diabetes Care.
Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, Stellfeld M, Tornøe K, Pratley RE; LEADER Publication Committee on behalf of the LEADER Trial Investigators
doi: 10.2337/dc18-1094.
COMMENTED
Diabetes - GeneralType 2 Diabetes
Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial
Lancet Diabetes Endocrinol.
Packer M, Claggett B, Lefkowitz MP, McMurray JJV, Rouleau JL, Solomon SD, Zile MR
doi: 10.1016/S2213-8587